drugset / Trial / NCT02280421
Drug-Drug Interaction Study: ASP2151 and Ciclosporin
RandomizedCrossoverOpen-labelOther
Summary
ASP2151 is an experimental treatment for herpes. Patients undergoing organ and tissue transplantation may be prescribed ciclosporin to suppress their immune system to give the transplant an increased chance of not being rejected. A patient with a compromised immune system is more susceptible to infections such as herpes, which will require treatment.
Timeline
- Start
- 2014-10
- Primary completion
- 2015-01
- Completion
- 2015-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amenamevir | Small molecule | 400 mg | — |
| Subject | Amenamevir | Small molecule | 1200 mg | — |
| Subject | Cyclosporine | Peptide | 100 mg | — |
Indications
No indication recorded.